1167 |
Latest Update on Upstream Atorvastatin Therapy |
In-Ho Chae |
May. 03. 10 |
1166 |
Nanoparticle or Nanomatrix Technologies for DES |
Ron Waksman |
May. 03. 10 |
1165 |
Bioabsorble or Free-Polymer DES: Current and New Technologies |
Gregg W. Stone |
May. 03. 10 |
1164 |
Systemic Review of Longterm Outcomes after First- vs. Second-Generation DES |
Adnan Kastrati |
May. 03. 10 |
1163 |
Guidelines and Current Practice in the Management of ACS Patients |
Young-Hak Kim |
May. 03. 10 |
1162 |
Antiplatelet Therapy in AF |
Sun Uck Kwon |
May. 03. 10 |
1161 |
Optimal Dosing of Antiplatelet Therapy in Patients With ACS Undergoing an Early Invasive Strategy: Insight from CURRENT-OASIS7 Trial |
David Joel Cohen |
May. 03. 10 |
1160 |
DES of the Future: Design Goals and Challenges |
Martin Bert Leon |
May. 03. 10 |
1159 |
Relevant Clinical Trials Designs: Balancing Regulatory and Medical Evidence Needs |
Ian T. Meredith |
May. 03. 10 |
1158 |
Early DES - What Did We Learn - Updates from the ZEST Trial |
Duk-Woo Park |
May. 03. 10 |